US FDA approves a weight loss drug for treating ‘serious’ fatty liver disease; here’s what you need to know |
The US Food and Drug Administration (FDA) has officially approved semaglutide, a drug widely known for weight loss and diabetes control, for treating metabolic associated steatohepatitis (MASH). This approval marks a major advancement in liver disease treatment, as MASH is a progressive condition caused by fat buildup and inflammation in the liver. Often symptomless in…